Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway

C. S. Craft, D. Romero, C. P.H. Vary, R. C. Bergan

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Fingerprint

Dive into the research topics of 'Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway'. Together they form a unique fingerprint.

Medicine & Life Sciences